Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Maria Vincenza Mastrolia, Luisa Galli, Maurizio De Martino & Elena Chiappini. (2017) Use of tigecycline in pediatric clinical practice. Expert Review of Anti-infective Therapy 15:6, pages 605-612.
Read now
Read now
Burke A. Cunha, Jeffrey Baron & Cheston B. Cunha. (2017) Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited. Expert Review of Anti-infective Therapy 15:3, pages 257-267.
Read now
Read now
Quanhathai Kaewpoowat & Luis Ostrosky-Zeichner. (2015) Tigecycline: a critical safety review. Expert Opinion on Drug Safety 14:2, pages 335-342.
Read now
Read now
Michael J. Satlin, David P. Calfee, Liang Chen, Kathy A. Fauntleroy, Stephen J. Wilson, Stephen G. Jenkins, Eric J. Feldman, Gail J. Roboz, Tsiporah B. Shore, David C. Helfgott, Rosemary Soave, Barry N. Kreiswirth & Thomas J. Walsh. (2013) Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia & Lymphoma 54:4, pages 799-806.
Read now
Read now
Gary P Wormser & Susan O’Connell. (2011) Treatment of infection caused by Borrelia burgdorferi sensu lato. Expert Review of Anti-infective Therapy 9:2, pages 245-260.
Read now
Read now
Mary L Townsend, Melanie W Pound & Richard H Drew. (2011) Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. Infection and Drug Resistance 4, pages 77-86.
Read now
Read now
F. Menichetti. (2009) Tigecycline: a New Treatment Option for Intra-abdominal Infections. Journal of Chemotherapy 21:sup1, pages 36-38.
Read now
Read now
Mary L Townsend, Melanie W Pound & Richard H Drew. (2007) Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections. Therapeutics and Clinical Risk Management 3:6, pages 1059-1070.
Read now
Read now
Despoina Koulenti & Jordi Rello. (2006) Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opinion on Pharmacotherapy 7:12, pages 1555-1569.
Read now
Read now
Articles from other publishers (44)
Kaan Aslan, Ömer Kiliç, Eylem Kiral, Gürkan Bozan, Özcan Bör & Ener Çağrı Dinleyici. (2022) Clinical and laboratory responses to tigecycline in children. Journal of Clinical Pharmacy and Therapeutics 47:10, pages 1585-1590.
Crossref
Crossref
Zhenwei Yu, Yuhua Zhao, Jiayi Jin, Jianping Zhu, Lingyan Yu & Gang Han. (2022) Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study. International Journal of Infectious Diseases 120, pages 59-64.
Crossref
Crossref
Sajad Yaghoubi, Angelina Olegovna Zekiy, Marcela Krutova, Mehrdad Gholami, Ebrahim Kouhsari, Mohammad Sholeh, Zahra Ghafouri & Farajolah Maleki. (2021) Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. European Journal of Clinical Microbiology & Infectious Diseases 41:7, pages 1003-1022.
Crossref
Crossref
Bing Leng, Genquan Yan, Cuicui Wang, Chengwu Shen, Wen Zhang & Wei Wang. (2021) Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline. Journal of Global Antimicrobial Resistance 25, pages 315-322.
Crossref
Crossref
Heather Davis, Ryan Brown, Deborah Ashcraft & George Pankey. (2020) In vitro synergy with fosfomycin plus doxycyclin against linezolid and vancomycin-resistant Enterococcus faecium. Journal of Global Antimicrobial Resistance 22, pages 78-83.
Crossref
Crossref
Jemila C. Kester, Douglas K. Brubaker, Jason Velazquez, Charles Wright, Douglas A. Lauffenburger & Linda G. Griffith. (2020)
Clostridioides difficile
-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms
. Antimicrobial Agents and Chemotherapy 64:4.
Crossref
Crossref
Jinhong Gong, Dan Su, Jingjing Shang, Hai Yu, Guantao Du, Ying Lin, Zhiqiang Sun & Guangjun Liu. (2019) Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases. Medicine 98:38, pages e17091.
Crossref
Crossref
Shada Y. Elhayek, Mohammad A. Fararjeh, Areej M. Assaf, Eman Y. Abu-Rish & Yasser Bustanji. (2018) Immunomodulatory Effects of Tigecycline in Balb/C Mice. Acta Pharmaceutica 68:4, pages 457-469.
Crossref
Crossref
Jeffrey Baron, Shuntao Cai, Natalie Klein & Burke Cunha. (2018) Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness. Journal of Clinical Medicine 7:3, pages 49.
Crossref
Crossref
Sebastian G. Wicha, Otto R. Frey, Anka C. Roehr, Johann Pratschke, Martin Stockmann, Rawan Alraish, Tilo Wuensch & Magnus Kaffarnik. (2017) Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study. International Journal of Antimicrobial Agents 50:4, pages 557-563.
Crossref
Crossref
Gregory A. Reed, Gary J. Schiller, Suman Kambhampati, Martin S. Tallman, Dan Douer, Mark D. Minden, Karen W. Yee, Vikas Gupta, Joseph Brandwein, Yulia Jitkova, Marcela Gronda, Rose Hurren, Aisha Shamas‐Din, Andre C. Schuh & Aaron D. Schimmer. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Medicine 5:11, pages 3031-3040.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
2
4
.
J. Simkins, V. Muggia, H.W. Cohen & G.Y. Minamoto. (2014)
Carbapenem‐resistant
K
lebsiella pneumoniae
infections in kidney transplant recipients: a case–control study
. Transplant Infectious Disease 16:5, pages 775-782.
Crossref
Crossref
Dror Marchaim, Jason M. Pogue, Oran Tzuman, Kayoko Hayakawa, Paul R. Lephart, Hossein Salimnia, Theresa Painter, Marcus J. Zervos, Laura E. Johnson, Mary Beth Perri, Pamela Hartman, Rama V. Thyagarajan, Sharon Major, Melanie Goodell, Mohamad G. Fakih, Laraine L. Washer, Duane W. Newton, Anurag N. Malani, Jason M. Wholehan, Lona Mody & Keith S. Kaye. (2014) Major Variation in MICs of Tigecycline in Gram-Negative Bacilli as a Function of Testing Method. Journal of Clinical Microbiology 52:5, pages 1617-1621.
Crossref
Crossref
Alex Rodriguez-Palacios, Sanja Ilic & Jeffrey T. LeJeune. (2014)
Clostridium difficile
with Moxifloxacin/Clindamycin Resistance in Vegetables in Ohio, USA, and Prevalence Meta-Analysis
. Journal of Pathogens 2014, pages 1-7.
Crossref
Crossref
Elizabeth L Alexander, Michael J Satlin, Maria N Gamaletsou, Nikolaos V Sipsas & Thomas J Walsh. (2013) Worldwide challenges of multidrug-resistant bacteria in patients with hematologic malignancies. International Journal of Hematologic Oncology 2:5, pages 377-390.
Crossref
Crossref
German A. Contreras & Cesar A. Arias. 2012. Antibiotic Discovery and Development. Antibiotic Discovery and Development
617
648
.
Michael J. Satlin, Christine J. Kubin, Jill S. Blumenthal, Andrew B. Cohen, E. Yoko Furuya, Stephen J. Wilson, Stephen G. Jenkins & David P. Calfee. (2011) Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine. Antimicrobial Agents and Chemotherapy 55:12, pages 5893-5899.
Crossref
Crossref
Alexander Rodriguez-Ralacios, Mohammad Koohmaraie & Jeffrey T. Lejeune. (2011) Prevalence, Enumeration, and Antimicrobial Agent Resistance of Clostridium Difficile In Cattle At Harvest In The United States. Journal of Food Protection 74:10, pages 1618-1624.
Crossref
Crossref
C. Jacqueline, G. Amador, E. Batard, V. Le Mabecque, A.-F. Miegeville, D. Biek, J. Caillon & G. Potel. (2011) Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 66:4, pages 863-866.
Crossref
Crossref
Yun Cai, Rui Wang, Beibei Liang, Nan Bai & Youning Liu. (2011) Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease. Antimicrobial Agents and Chemotherapy 55:3, pages 1162-1172.
Crossref
Crossref
Joan M. Korth-Bradley, Susan J. Baird-Bellaire, Alain A. Patat, Steven M. Troy, Gabriele M. Böhmer, Christoph H. Gleiter, Reinhild Buecheler & Marsha Y. Morgan. (2011) Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis. The Journal of Clinical Pharmacology 51:1, pages 93-101.
Crossref
Crossref
. 2010. Meyler's Side Effects of Antimicrobial Drugs. Meyler's Side Effects of Antimicrobial Drugs
1
443
.
J.M. Entenza & P. Moreillon. (2009) Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. International Journal of Antimicrobial Agents 34:1, pages 8.e1-8.e9.
Crossref
Crossref
L.R. Peterson. (2008) Currently available antimicrobial agents and their potential for use as monotherapy. Clinical Microbiology and Infection 14, pages 30-45.
Crossref
Crossref
Lance R. Peterson. (2008) A review of tigecycline — the first glycylcycline. International Journal of Antimicrobial Agents 32, pages S215-S222.
Crossref
Crossref
Daniel Curcio. (2008) Comment: Tigecycline for the Treatment of Acinetobacter Infections: A Case Series. Annals of Pharmacotherapy 42:11, pages 1717-1718.
Crossref
Crossref
A. P. MacGowan. (2008) Tigecycline pharmacokinetic/pharmacodynamic update. Journal of Antimicrobial Chemotherapy 62:Supplement 1, pages i11-i16.
Crossref
Crossref
Daniel Curcio. (2008) Treatment of Recurrent Urosepsis with Tigecycline: a Pharmacological Perspective. Journal of Clinical Microbiology 46:5, pages 1892-1893.
Crossref
Crossref
S. Roveta, A. Marchese & E.A. Debbia. (2008) Tigecycline in vitro Activity against Gram-Negative and Gram-Positive Pathogens Collected in Italy. Chemotherapy 54:1, pages 43-49.
Crossref
Crossref
Tore Midtvedt. 2008. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
280
296
.
Christine M Slover, Keith A Rodvold & Larry H Danziger. (2007) Tigecycline: A Novel Broad-Spectrum Antimicrobial. Annals of Pharmacotherapy 41:6, pages 965-972.
Crossref
Crossref
S. A. Van Wart, B. B. Cirincione, E. A. Ludwig, A. K. Meagher, J. M. Korth-Bradley & J. S. Owen. (2007) Population Pharmacokinetics of Tigecycline in Healthy Volunteers. The Journal of Clinical Pharmacology 47:6, pages 727-737.
Crossref
Crossref
Richard H. Drew. (2012)
Emerging Options for Treatment of Invasive, Multidrug‐Resistant
Staphylococcus aureus
Infections
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:2, pages 227-249.
Crossref
Crossref
M. L. TOWNSEND, M. W. POUND & R. H. DREW. (2006) Tigecycline: a new glycylcycline antimicrobial. International Journal of Clinical Practice 60:12, pages 1662-1672.
Crossref
Crossref
Adam P. Fraise. (2006) Tigecycline: The answer to beta-lactam and fluoroquinolone resistance?. Journal of Infection 53:5, pages 293-300.
Crossref
Crossref
Marshall Feterl, Brenda Govan, Cathy Engler, Robert Norton & Natkunam Ketheesan. (2006) Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. International Journal of Antimicrobial Agents 28:5, pages 460-464.
Crossref
Crossref
Warren E Rose & Michael J Rybak. (2006) Tigecycline: First of a New Class of Antimicrobial Agents. Pharmacotherapy 26:8, pages 1099-1110.
Crossref
Crossref
Despoina Koulenti & Jordi Rello. (2006) Gram-negative bacterial pneumonia: aetiology and management. Current Opinion in Internal Medicine 5:4, pages 358-364.
Crossref
Crossref
J. Carlet & A. Tabah. (2006) Antibiothérapie des états infectieux graves. Médecine et Maladies Infectieuses 36:6, pages 299-303.
Crossref
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:6, pages i-xii.
Crossref
Crossref
Jean Carlet. (2006) Stratégie antibiotique au cours du choc septique. La Presse Médicale 35:3, pages 528-532.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2006. Annual Reports in Medicinal Chemistry Volume 41. Annual Reports in Medicinal Chemistry Volume 41
439
477
.
R. Zaragoza-Crespo & J.I. Blanes-Mompó. (2006) Infección y pie diabético. ¿Existen nuevas posibilidades terapéuticas?. Angiología 58:5, pages 347-356.
Crossref
Crossref